Microba Life Sciences Completes $5.41 Million Capital Raise to Expand Microbiome Testing Across Australia and UK

Microba's Microbiome Diagnostics Business and Market Position

Microba Life Sciences Limited operates at the forefront of microbiome health and human care, positioning itself as a provider of clinical-grade microbiome testing solutions designed to help people live healthier lives. The company's core business centres on the development and delivery of microbiome diagnostics across two primary geographical markets: Australia and the United Kingdom. Microba describes itself as being at the centre of world-leading science and insights related to microbiome health, backed by proprietary collaboration tools that support clinical adoption of its testing products.

The company's mission, as outlined in the announcement, is to deliver clinical-grade microbiome tests that help patients and healthcare providers make better health decisions. Microba's business model focuses on clinical adoption of its microbiome testing offerings, which generate revenue through the provision of diagnostic services to healthcare practitioners and patients across its operating regions. The expansion of this core diagnostics business across both Australia and the UK represents a key strategic priority, supported by the capital raised through the current funding round.

Details of the $5.41 Million Capital Raise Structure

The capital raising completed by Microba comprised two distinct components: an institutional Placement announced on 12 June 2026, and a Share Purchase Plan (SPP) that closed on 22 July 2026. Together, these mechanisms raised approximately $5.41 million before costs. The institutional Placement component raised $5.0 million, while the SPP contributed $407,500 to the total capital raised. The two-part structure allowed both institutional investors and eligible retail shareholders to participate in the funding round at the same share price, without brokerage or fees being applied to SPP participants.

The institutional Placement was executed in two tranches. The first tranche, comprising 91,344,455 New Shares, settled on 17 June 2026. The second tranche, comprising 8,659,785 New Shares, required shareholder approval and was subsequently approved at Microba's general meeting held on 24 July 2026. This staged approach to the Placement allowed the company to secure immediate funding while managing regulatory and shareholder approval requirements separately. The combination of the Placement tranches and the SPP reflects a comprehensive capital-raising strategy designed to engage both institutional and retail shareholders in Microba's growth initiatives.

Share Purchase Plan Terms and Shareholder Participation

The Share Purchase Plan offered eligible shareholders in Australia and New Zealand the opportunity to invest in Microba on terms identical to those available to institutional Placement investors. The SPP was conducted under a prospectus dated 19 June 2026, issued in accordance with section 713 of the Corporations Act 2001 (Cth). Eligible shareholders could apply to purchase New Shares at $0.05 per share, with every valid application satisfied in full and no scale back applied, meaning all eligible investors who applied received their full allocation.

The SPP raised $407,500 through the issue of 8,150,000 New Shares at the offer price of $0.05 per share. In addition to the New Shares, eligible SPP shareholders receive one free attaching New Option for every New Share issued, totalling 8,150,000 New Options. These New Options are exercisable at $0.0625 per option and expire three years from their date of issue. The New Shares issued under the SPP rank equally with existing Microba ordinary shares from their date of issue, ensuring that new SPP participants hold shares with the same rights and entitlements as existing shareholders. The provision of free attaching options represents an additional incentive to encourage retail shareholder participation in the capital raise.

Shareholder Approval and Regulatory Approvals for the Placement Second Tranche

The issuance of securities under the SPP and the second tranche of the institutional Placement were both subject to shareholder approval. Microba held its general meeting on 24 July 2026, at which all resolutions required for the capital raising were put to shareholders. The company received approval for all resolutions at this general meeting, clearing the path for the issue of the remaining securities. Following this approval, Microba proceeded with issuing the second tranche of the Placement, comprising 8,659,785 New Shares, alongside the SPP securities and the free attaching options.

The successful shareholder approval demonstrates investor backing for Microba's capital expansion and strategic initiatives. The timing of the general meeting approval on 24 July 2026, just days before the scheduled issue of securities on 29 July 2026, reflects a streamlined process that allowed the company to move quickly from shareholder approval to settlement. The regulatory framework governing the Placement and SPP, including the prospectus issued under the Corporations Act 2001 (Cth), ensured that both institutional and retail investors received appropriate disclosure and had equal access to investment opportunities at the same price point.

New Options Terms and Long-Term Investment Incentive

As part of the capital raising, Microba has issued a substantial number of free attaching New Options to both Placement and SPP participants. The institutional Placement investors will receive 100,004,240 New Options in total, comprising one New Option for every Placement New Share issued across both tranches of the Placement. SPP investors will receive 8,150,000 New Options, also on a one-for-one basis with shares issued. All New Options issued under both the Placement and SPP are exercisable at $0.0625 per option and expire three years from their date of issue, providing investors with a three-year window to exercise their options if they choose to do so.

The inclusion of free attaching options serves multiple strategic purposes. For investors, the options provide upside potential if Microba's share price appreciates above the exercise price during the three-year exercise period. For Microba, the options represent a mechanism to secure additional capital if and when investors exercise their rights, providing the company with a potential future capital injection. The exercise price of $0.0625 represents a 25 percent premium to the $0.05 share issue price, establishing a clear performance threshold that the company would need to exceed for the options to become in-the-money and attractive for exercise by investors.

Use of Proceeds and Strategic Growth Initiatives

Microba has indicated that the proceeds from the capital raising will support several key business objectives. The funds will strengthen the company's balance sheet and support the continued expansion of clinical adoption of Microba's microbiome testing across its Australian and United Kingdom operations. Beyond expanding existing diagnostic offerings, the capital will also facilitate the delivery of a new testing product to market, representing a product development initiative that has been in progress and which the company intends to launch with the support of this capital injection. Additionally, the proceeds will support working capital requirements, ensuring Microba has sufficient liquidity to fund its operations and growth initiatives.

The strategic use of proceeds reflects Microba's focus on geographic expansion and product innovation within the microbiome diagnostics sector. The company's emphasis on clinical adoption across two established markets—Australia and the UK—suggests a targeted approach to growing revenue from healthcare practitioners and patients in these regions. The launch of a new testing product indicates that Microba's product pipeline extends beyond its existing diagnostic offerings, suggesting the company is developing enhanced or differentiated microbiome testing capabilities. The allocation of capital to working capital ensures that the company maintains operational flexibility as it pursues these growth initiatives.

Issue Timeline and Expected Settlement Dates for New Securities

Microba has provided investors with a detailed timeline for the issue and trading of new securities. The New Shares and New Options issued under both the SPP and the institutional Placement are expected to be issued on Wednesday, 29 July 2026. Following this issue date, trading of the New Shares issued under the SPP is expected to commence on Thursday, 30 July 2026. Holding statements confirming investors' shareholdings and options are expected to be despatched on Friday, 31 July 2026. The company has noted that these dates are indicative only and may change at the company's discretion, subject to the ASX Listing Rules and the Corporations Act 2001 (Cth).

This timetable reflects a compressed settlement schedule designed to bring new securities to market swiftly following shareholder approval. The one-day lag between issue and the commencement of trading allows the company's registry to process the issue and prepare for trading activity. The expected despatch of holding statements on 31 July 2026 provides investors with formal confirmation of their holdings within a week of the issue date. The notation that dates may change at the company's discretion, subject to regulatory requirements, acknowledges that administrative or regulatory issues could affect the timeline, but indicates Microba's intention to adhere to the published schedule absent unforeseen circumstances.

Capital Raising Announcement Context and Institutional Investor Support

The institutional Placement announced on 12 June 2026 was the initial component of Microba's two-part capital raising strategy. This Placement component raised $5.0 million from institutional investors before costs, and included the settlement of the first tranche on 17 June 2026 at a share price of $0.05. The subsequent announcement of the SPP complemented the institutional Placement by offering eligible retail shareholders the opportunity to invest at the same price as institutional investors, reinforcing Microba's commitment to treating retail shareholders equitably.

Chief Executive Officer Luke Reid provided context for the capital raise in the company update, expressing gratitude to shareholders for their continued support and noting that the completion of the capital raising gives Microba the financial strength to continue expanding clinical adoption of its microbiome testing. Reid's statement emphasises the company's conviction in the market opportunity ahead and its intention to leverage the capital to drive growth in existing markets while also bringing new products to market. The completion of the capital raise represents a significant milestone in Microba's funding journey and provides the financial foundation for the company's stated growth objectives.

Sector Context and Competitive Positioning in Microbiome Diagnostics

Microba operates within the broader microbiome diagnostics and personalized medicine sector, which has attracted significant research, development, and commercial investment in recent years. The microbiome—the collection of microorganisms inhabiting the human gut and other body sites—has become an established focus of clinical research, with potential applications across gastroenterology, metabolic health, immunology, and mental health. The commercialisation of microbiome testing for clinical use remains a growth area, with early-mover advantages accruing to companies that can establish clinical credibility and secure adoption among healthcare practitioners.

Microba's positioning as a provider of clinical-grade microbiome testing, with operations established in both Australia and the UK, reflects a focus on developed healthcare markets where practitioners have access to advanced diagnostic capabilities and patients can afford testing services. The emphasis on clinical adoption and the planned launch of a new testing product suggest that Microba is focused on continuously enhancing its diagnostic offerings and expanding the range of clinical conditions that its testing can address. The capital raise provides Microba with the resources to compete effectively in this dynamic sector and to scale its business as clinical adoption of microbiome testing expands.

Risks and Operational Considerations for Investors

While Microba has raised capital to support its growth initiatives, investors should be cognisant of risks inherent to the company's business model and market position. The microbiome diagnostics sector remains relatively nascent, with ongoing clinical research and regulatory scrutiny of testing claims. Microba's ability to achieve its stated goal of expanding clinical adoption depends on healthcare practitioners and patients in Australia and the UK accepting microbiome testing as a valuable diagnostic tool. Reimbursement arrangements, whether through government healthcare systems or private insurers, can materially affect demand for diagnostic services and represent an operational risk beyond the company's direct control.

The company's expansion into new products and geographic markets carries execution risk, as new product launches require validation and approval processes, and geographic expansion demands local market knowledge and regulatory compliance. The timing of the new product launch, the level of clinical validation required before launch, and the pace of market adoption following launch all represent uncertainties that could affect the company's ability to realise the benefits anticipated from the capital raised. Additionally, as a relatively small-cap company in the diagnostic services sector, Microba faces competitive pressures from larger established diagnostic companies and other emerging microbiome testing providers, which could constrain its market share or pricing power.